12627NRG-BR007-NCT04852887OpenA PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE </= 18 BREAST CANCERThis Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.NRG-BR007NCT04852887NationalAdultTreatmentOther: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)IIIBreastThis study investigates the following condition or disease: Stage I Breast Cancer Fowler, PaulGeorgetown University Medical Center; Lombardi Comprehensive Cancer Center; MedStar Health Medical Center at BelAir; Medstar Franklin Square Medical Center; Medstar Good Samaritan HospitalBreastOncology GroupMHRI Oncology Baltimore; NCA MU NCORP 2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>